Asthma Clinical Trial
Official title:
The Association of Asthma With Systemic Inflammation and Oxidative Stress, and Its Effect on the Risk of Cardiovascular Morbidity in Adult With Stable Asthma
Asthma is a chronic airway inflammation which involves the interplay of different types of inflammatory cells and cytokines in the airway. The presence of systemic inflammation and oxidative stress in asthma suggests that it has a propensity to develop cardiovascular morbidity. Recent small scale studies have demonstrated that asthma severity may be associated with both airway and systemic inflammation. The investigators' study aims at linking asthma severity to airway and systemic inflammation, and subsequently to cardiovascular morbidity if a significant association of the aforementioned is present. The role of airway inflammation in contribution to systemic inflammation , and potential interaction between these two conditions will also be studied.
Asthma is a chronic inflammatory airway disorder, associated with airflow obstruction and
bronchial hyper-responsiveness, which affects about 10% of population in Hong Kong. It has
been a major respiratory disease in Hong Kong that carries significant morbidity and high
hospitalization burden in all ages. The use of long-term inhaled corticosteroid treatment in
recent decades has become the cornerstone in the treatment of most patients with persistent
asthma with reduction in its mortality. The ultimate goal of treatment is to achieve optimal
control of airway inflammation and asthma-related mortality and morbidity.
In recent studies on the evaluation of airway and systemic inflammation in patients with
asthma, various biomarkers have been measured in exhaled breath condensate (EBC), like
nitric oxide, nitrates/nitrites and 8-isoprostane. Similarly, measurement of biomarkers in
blood, notably high-sensitivity c-reactive protein (hs-CRP), 8-isoprostane and antioxidants
(catalase, superoxide dismutase, glutathione peroxidase, glutathione), has also been used to
reflect the levels of systemic inflammation and oxidative stress.
There has been substantial evidence from landmark epidemiological studies in the past 10
years, predominantly based on plasma hs-CRP, that chronic low grade systemic inflammation is
an independent predictor for the development of hypertension, myocardial infarction, stroke,
cardiovascular death and peripheral vascular disease. A dose-dependent risk association
between hs-CRP and these cardiovascular morbidities has also been consistently demonstrated.
Moreover, there has been overwhelming data to suggest the association between oxidative
stress and the development cardiovascular disease. This association is easily understood in
light of the cellular damages and endothelial dysfunction due to oxidative stress, which may
lead to the development of atherosclerosis and cardiovascular morbidity.
In chronic obstructive pulmonary disease (COPD), a chronic inflammatory airway disorder
characterized by irreversible airflow obstruction induced mainly by tobacco smoking, studies
have demonstrated that, in acute exacerbations of COPD and smoking, there is a marked
imbalance of redox status. The increased oxidative stress results in the inactivation of
alveolar antiproteases, airspace epithelial damage, increased influx of neutrophils into
lung tissue and the expression of pro-inflammatory mediators. Similarly, patients with COPD
also have increase neutrophils, lymphocytes and TNF-α in the peripheral blood. In fact, many
studies have demonstrated the existence of low grade systemic inflammation and oxidative
stress in patients with COPD. Important studies published in recent 5 years have also linked
the elevation of these systemic biomarkers, in a dose-dependent manner, to COPD severity and
increased prevalence of cardiovascular and cerebrovascular morbidity and mortality in
patients with COPD.
On the other hand, chronic airway inflammation is also the hallmark of asthma which involves
the interplay of different types of inflammatory cells, including T-lymphocytes,
eosinophils, neutrophils, macrophages and cytokines in the airway. Although the pathogenesis
of asthma is incompletely understood, studies have shown that it is associated with a state
of increased free radical formation, because cells derived from airways and peripheral blood
of patients with asthma generate increased amount of reactive oxygen species, the level of
which is related to severity of asthma. Besides, airway biomarkers indicating airway
inflammation and oxidative stress have been consistently shown to be positively related to
asthma severity and asthma control, which can be alleviated with treatment by inhaled
corticosteroids. Additionally, recent preliminary studies have indicated that, apart from
the presence of chronic airway inflammation (elevated EBC nitric oxide, EBC
nitrites/nitrates and EBC 8-isoprostane), asthma may also be associated with chronic low
grade systemic inflammation (elevation of plasma hs-CRP) and increased oxidative stress
(increased 8-isoprostane; altered erythrocyte superoxide dismutase, catalase, glutathione
peroxidase and glutathione).
Whether the presence of systemic inflammation and oxidative stress in asthma is actually a
consequence of "overspill" of uncontrolled airway inflammation or the existence of an
extrapulmonary source of inflammation remains unknown. At the moment, there is only little
evidence on the correlation of airway and systemic inflammation in asthma, as well as the
relation of systemic inflammation and oxidative stress to asthma severity. Intuitively, as
in COPD, asthma-related systemic inflammation may as well increase the propensity for
development of cardiovascular and cerebrovascular diseases. However, there is also a lack of
study that describes the risk of cardiovascular outcomes of asthma-related systemic
inflammation and oxidative stress.
Therefore, we conduct the current study with the primary objective to investigate the
association of asthma severity with systemic inflammation and oxidative stress, and its
effect on the risk of various cardiovascular morbidities. The secondary objective is to
correlate airway inflammation and oxidative stress with systemic inflammation and oxidative
stress in stable asthmatics.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|